| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Correction to Lancet Microbe 2021; published online Nov 16. https://doi.org/10.1016/S2666-5247(21)00211-1
|
|
|
|
3 |
1 |
p. e8
|
article
|
| 2 |
Correction to Lancet Microbe 2021; published online Nov 11. https://doi.org/10.1016/S2666-5247(21)00277-9
|
|
|
|
3 |
1 |
p. e8
|
article
|
| 3 |
Correction to Lancet Microbe 2021; published online Nov 23. https://doi.org/10.1016/S2666-5247(21)00209-3
|
|
|
|
3 |
1 |
p. e8
|
article
|
| 4 |
Current malaria infection, previous malaria exposure, and clinical profiles and outcomes of COVID-19 in a setting of high malaria transmission: an exploratory cohort study in Uganda
|
Achan, Jane
|
|
|
3 |
1 |
p. e62-e71
|
article
|
| 5 |
Direct diagnosis of Pasteurella multocida meningitis using next-generation sequencing
|
Morsli, M
|
|
|
3 |
1 |
p. e6
|
article
|
| 6 |
Global distribution of human hookworm species and differences in their morbidity effects: a systematic review
|
Clements, Archie C A
|
|
|
3 |
1 |
p. e72-e79
|
article
|
| 7 |
Leaving no one behind: the need for a truly global response to antimicrobial resistance
|
Goldberg, Jacob
|
|
|
3 |
1 |
p. e2-e3
|
article
|
| 8 |
Malaria progress stumbles, but new tools offer hope
|
The Lancet Microbe,
|
|
|
3 |
1 |
p. e1
|
article
|
| 9 |
Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
|
Cromer, Deborah
|
|
|
3 |
1 |
p. e52-e61
|
article
|
| 10 |
No collateral antibiotic sensitivity by alternating antibiotic pairs
|
Ma, Yeping
|
|
|
3 |
1 |
p. e7
|
article
|
| 11 |
Polio vaccination in Afghanistan
|
Bagcchi, Sanjeet
|
|
|
3 |
1 |
p. e10
|
article
|
| 12 |
Pyronaridine–artesunate or dihydroartemisinin–piperaquine combined with single low-dose primaquine to prevent Plasmodium falciparum malaria transmission in Ouélessébougou, Mali: a four-arm, single-blind, phase 2/3, randomised trial
|
Stone, William
|
|
|
3 |
1 |
p. e41-e51
|
article
|
| 13 |
Safety and immunogenicity of ChAdOx1 MERS vaccine candidate in healthy Middle Eastern adults (MERS002): an open-label, non-randomised, dose-escalation, phase 1b trial
|
Bosaeed, Mohammad
|
|
|
3 |
1 |
p. e11-e20
|
article
|
| 14 |
Severe breakthrough COVID-19 cases in the SARS-CoV-2 delta (B.1.617.2) variant era
|
Wang, Stephen Y
|
|
|
3 |
1 |
p. e4-e5
|
article
|
| 15 |
T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study
|
Angyal, Adrienn
|
|
|
3 |
1 |
p. e21-e31
|
article
|
| 16 |
Virus persistence after recovery from acute Lassa fever in Nigeria: a 2-year interim analysis of a prospective longitudinal cohort study
|
Thielebein, Anke
|
|
|
3 |
1 |
p. e32-e40
|
article
|
| 17 |
Worrying global decline in measles immunisation
|
Venkatesan, Priya
|
|
|
3 |
1 |
p. e9
|
article
|
Journal description